Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Saniona","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from Boehringer Ingelheim","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Saniona"},{"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Initiates Positron Emission Tomography (PET) Stage of SAN711 Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Saniona"},{"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Saniona"}]

Saniona

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Details:

Data from the trial demonstrated that SAN711 was safe and well tolerated across all dosing cohorts with a favorable absorption and distribution profile. There were no serious adverse events, and all subjects completed the study.

Lead Product(s): SAN711

Therapeutic Area: Neurology Product Name: SAN711

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2022

ASK
US

Upload
your Pipeline Activity

Saniona

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Saniona Initiates Positron Emission Tomography (PET) Stage of SAN711 Phase 1 Clinical Trial

Details:

SAN711 is an investigational, potential first-in-class positive allosteric modulator of GABA-A α3 receptors, may have the potential to restore spinal inhibitory tone and prevent abnormal pain signaling to the brain.

Lead Product(s): SAN711

Therapeutic Area: Neurology Product Name: SAN711

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2022

ASK
US

Upload
your Pipeline Activity

Saniona

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from Boehringer Ingelheim

Details:

The termination of the GABAa5 program provides Saniona with rights to a portfolio of more than 800 molecules; the company intends to evaluate their applicability in rare diseases.

Lead Product(s): SAN711

Therapeutic Area: Neurology Product Name: SAN711

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination November 05, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY